0000899243-21-009499.txt : 20210303 0000899243-21-009499.hdr.sgml : 20210303 20210303183921 ACCESSION NUMBER: 0000899243-21-009499 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210301 FILED AS OF DATE: 20210303 DATE AS OF CHANGE: 20210303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MAHAFFY PATRICK J CENTRAL INDEX KEY: 0001266569 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 21711308 MAIL ADDRESS: STREET 1: C/O CLOVIS ONCOLOGY, INC. STREET 2: 5500 FLATIRON PARKWAY, SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-01 0 0001466301 Clovis Oncology, Inc. CLVS 0001266569 MAHAFFY PATRICK J C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER CO 80301 1 1 0 0 See Remarks Stock Option (right to buy) 6.23 2021-03-01 4 A 0 220000 0.00 A 2031-03-01 Common Stock 220000 220000 D Stock Option (right to buy) 6.23 2021-03-01 4 A 0 80000 0.00 A 2031-03-01 Common Stock 80000 80000 D Stock Option (right to buy) 6.23 2021-03-01 4 A 0 40000 0.00 A 2031-03-01 Common Stock 40000 40000 D Stock Option (right to buy) 6.23 2021-03-01 4 A 0 40000 0.00 A 2031-03-01 Common Stock 40000 40000 D The option shall vest as to 25% of the shares on March 1, 2022, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. The option shall vest in the event Product Revenues for the Company's fiscal year ending December 31, 2021 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board on December 8, 2020. The option shall vest upon the selection of an alpha-emitter agent for use in the study of the Company's product candidate FAP-2286 on or before December 31, 2021. The option shall vest upon the enrollment of three dose cohorts in the Company's LuMIERE study on or before December 31, 2021. President and Chief Executive Officer /s/ Patrick J. Mahaffy 2021-03-03